{"id":4547,"date":"2026-04-20T15:18:21","date_gmt":"2026-04-20T15:18:21","guid":{"rendered":"https:\/\/tradertideinsights.com\/?p=4547"},"modified":"2026-04-20T15:18:21","modified_gmt":"2026-04-20T15:18:21","slug":"eli-lilly-to-acquire-kelonia-in-7-billion-cancer-therapy-push","status":"publish","type":"post","link":"https:\/\/tradertideinsights.com\/?p=4547","title":{"rendered":"Eli Lilly to acquire Kelonia in $7 billion cancer therapy push"},"content":{"rendered":"
<\/div>\n

Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments.<\/p>\n

The agreement includes an upfront payment of $3.25 billion, with additional payouts tied to clinical, regulatory and commercial milestones. <\/p>\n

The transaction is expected to close in the second half of 2026.<\/p>\n

The Kelonia acquisition is expected to bolster Lilly\u2019s position in the global oncology market, estimated at $240 billion, while advancing its ambitions in cutting-edge cell therapies.<\/p>\n

Cancer therapies remain a key pillar of it’s business, generating $9.4 billion in revenue last year out of total sales of $65.2 billion.<\/p>\n

Bet on next-generation CAR-T therapies<\/h2>\n

Kelonia is developing an emerging form of cell therapy known as in vivo CAR-T, which aims to reprogram a patient\u2019s immune cells directly inside the body to attack cancer. <\/p>\n

This approach differs from existing CAR-T treatments, where cells are extracted, engineered in laboratories and then reinfused into patients.<\/p>\n

\u201cIt\u2019s an intravenously delivered therapy, one time,\u201d said Jacob Van Naarden, president of Lilly oncology. <\/p>\n

\u201cIt targets your body\u2019s T-cells, transforms them into attacking the cancer in the body, and requires no preconditioning at all.\u201d<\/p>\n

The simplified process could make such therapies more widely accessible, removing the need for complex manufacturing and chemotherapy preconditioning that currently limits treatment to specialised centres.<\/p>\n

Competition intensifies in blood cancer treatments<\/h2>\n

The deal comes amid heightened competition in the fast-growing market for blood cancer therapies. <\/p>\n

CAR-T treatments have shown strong results in conditions such as multiple myeloma, drawing significant investment from major pharmaceutical companies.<\/p>\n

Johnson & Johnson reported $1.89 billion in sales last year from its CAR-T therapy Carvykti. <\/p>\n

Meanwhile, Gilead Sciences recently acquired its partner Arcellx and its competing therapy for $7.8 billion.<\/p>\n

Lilly\u2019s move signals its intent to become a stronger player in hematology, where it currently has a limited presence with a single approved blood cancer drug, Jaypirca.<\/p>\n

Early-stage technology with long-term potential<\/h2>\n

Kelonia\u2019s lead programme focuses on multiple myeloma, a form of blood cancer, though it remains in early stages of development. <\/p>\n

In January, the company said the Food and Drug Administration had cleared its therapy for Phase 1 trials to assess safety in a small group of patients.<\/p>\n

Despite the early stage, Lilly executives described the underlying data as highly promising. <\/p>\n

The in vivo approach could potentially transform treatment by eliminating the need for personalised cell manufacturing, which is both costly and time-consuming.<\/p>\n

If successful, the technology may broaden access to advanced therapies beyond large academic medical centres, where current CAR-T procedures are typically administered.<\/p>\n

Part of broader dealmaking strategy<\/h2>\n

The acquisition is the latest in a series of deals by Lilly, which has been leveraging strong cash flows from its weight-loss drugs to expand its pipeline across therapeutic areas.<\/p>\n

Last month, the company agreed to acquire Centessa Pharmaceuticals for about $6.3 billion to strengthen its neuroscience portfolio. <\/p>\n

Earlier this year, it struck deals to buy Orna Therapeutics for up to $2.4 billion and Ventyx Biosciences for around $1.2 billion.<\/p>\n<\/p>\n

The post Eli Lilly to acquire Kelonia in $7 billion cancer therapy push<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments.The agreement includes an upfront payment of $3.25 billion, with additional payouts tied to clinical, regulatory and commercial milestones. The transaction is expected to close in…<\/p>\n","protected":false},"author":1,"featured_media":4548,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/4547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4547"}],"version-history":[{"count":0,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/4547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/media\/4548"}],"wp:attachment":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}